Skip to content

13F-HR/A filed by Boxer Capital Management, LLC

Boxer Capital Management, LLC filed this 13F-HR/A for the quarter ended 2025-09-30, filed 2026-02-17, with 34 holding rows worth $313,726,904.

Accession
0002018299-26-000005
Filed
2026-02-17
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2025

A holdings report, amendment of type restatement, 34 entries on the cover page, a total value of $313,726,904 stated on the cover page (in dollars after the unit check, H1), rows summing to $313,726,904 with VALUE read as dollars as filed, 13F file number 028-25329. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
TANGO THERAPEUTICS INC87583X109COM9,771,485$82,080,474dollars as filed
UNIQURE NVN90064101SHS800,000$46,696,000dollars as filed
REVOLUTION MEDICINES INC COM76155X100Stock400,000$18,680,000dollars as filed
KYMERA THERAPEUTICS INC501575104COM319,100$18,061,060dollars as filed
KODIAK SCIENCES INC50015M109COM750,000$12,277,500dollars as filed
PTC THERAPEUTICS INC69366J200COM200,000$12,274,000dollars as filed
AMYLYX PHARMACEUTICALS INC03237H101COM900,000$12,231,000dollars as filed
UROGEN PHARMA LTDM96088105COMMON STOCK575,000$11,471,250dollars as filed
MERUS N VN5749R100COM120,000$11,298,000dollars as filed
CYTOKINETICS INC23282W605COM NEW200,000$10,992,000dollars as filed
ABIVAX SA-00370M103SPONSORED ADS120,000$10,188,000dollars as filed
PROTAGONIST THERAPEUTICS74366E102COM110,000$7,307,300dollars as filed
NEKTAR THERAPEUTICS640268306COMMON STOCK125,000$7,112,500dollars as filed
CRESCENT BIOPHARMA INCG2545C104COMMON STOCK453,686$5,394,326dollars as filed
INOVIO PHARMACEUTICALS I45773H409COMMON STOCK2,300,000$5,382,000dollars as filed
SAREPTA THERAPEUTICS INC803607100COM250,000$4,817,500dollars as filed
CIDARA THERAPEUTICS INC171757206COM NEW48,000$4,596,480dollars as filed
CELCUITY INC15102K100COM90,000$4,446,000dollars as filed
REPLIMUNE GROUP INC76029N106COMMON STOCK1,050,000$4,399,500dollars as filed
SOLID BIOSCIENCES INC83422E204COMMON STOCK600,000$3,702,000dollars as filed
DENALI THERAPEUTICS INC COM24823R105Stock250,000$3,630,000dollars as filed
PRECIGEN INC74017N105COM850,000$2,796,500dollars as filed
APOGEE THERAPEUTICS INC COM03770N101Stock50,000$1,986,500dollars as filed
MIND MEDICINE MINDMED INC60255C885COM NEW163,500$1,927,665dollars as filed
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD61559X104Stock250,000$1,792,500dollars as filed
NURIX THERAPEUTICS INC67080M103COMMON STOCK175,000$1,617,000dollars as filed
AVALO THERAPEUTICS INC05338F306COMMON STOCK125,000$1,588,750dollars as filed
Milestone Pharmaceuticals Inc59935V107COM666,666$1,333,332dollars as filed
PEPGEN INC COM713317105Stock250,000$1,155,000dollars as filed
LB PHARMACEUTICALS INC50180M108COMMON STOCK70,000$1,105,300dollars as filed
Instil Bio Inc45783C200COM NEW60,700$1,084,102dollars as filed
KALVISTA PHARMACEUTICALS INC483497103COM20,400$248,472dollars as filed
NUVATION BIO INC67080N119WARR266,666$53,893dollars as filed
SURROZEN INC86889P117*W EXP 08/01/20366,666$1,000dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0002018299-25-000012 superseded2025-11-14acceptance time not in the bulk data set
13F-HR/A 0002018299-26-000005this filing2026-02-17acceptance time not in the bulk data set